Chai Discovery

Visit Website

Chai Discovery builds the computer-aided design suite for molecules — Chai-1/Chai-2 AI models for structure prediction and de novo drug design, powering discovery programs at Novartis, Pfizer, Eli Lilly and argenx.

Headquarters

San Francisco, USA

Year Founded

2024

Founders

Joshua Meier, Jack Dent, Matthew McPartlon, Jacques Boitreaud

Country

United States

Financial Information

Funding Stage

Series C

Recent Funding

$630M

Funding By

Index Ventures (Series C lead)

Core Technology

Chai-1/Chai-2 biomolecular structure & design models

Product Type

Drug + AI Platform

Pipeline Stage (Very Important)

Discovery

Regulatory Status

IND Filed: No
FDA/EMA Status: N/A
Clinical Trial Registration: N/A
Patents / IP Status: Building IP portfolio

Partnerships

Pharma Collaborations

Novartis, Pfizer, Eli Lilly, argenx

Academic / Hospital Tie-ups

Ex-Meta AI / OpenAI research founders

CRO/CDMO Partnerships

None disclosed

Market & Differentiation

4 top-10 pharma deals in under 2 years; atomic-precision antibody design